- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 134 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- October 2024
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- December 2023
- 111 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2024
- 158 Pages
Global
From €3969EUR$4,175USD£3,334GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Drug Pipelines
- June 2023
- 122 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- June 2023
- 57 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- July 2023
- 102 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2022
- 40 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 59 Pages
Global
From €1901EUR$2,000USD£1,597GBP

The Thromboembolism Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of thromboembolic diseases. These drugs are used to reduce the risk of blood clots forming in the arteries and veins, which can lead to serious health complications such as stroke, heart attack, and pulmonary embolism. Thromboembolism drugs are typically anticoagulants, which work by preventing the formation of clots, or thrombolytics, which work by breaking down existing clots.
The Thromboembolism Drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Commonly prescribed drugs include warfarin, heparin, and low molecular weight heparins. Newer drugs such as direct oral anticoagulants (DOACs) are also becoming increasingly popular.
Some of the major companies in the Thromboembolism Drug market include Pfizer, Sanofi, Bayer, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more